Reported 8 months ago
When considering high-yield dividend stocks in the pharmaceutical sector, Pfizer and Bristol Myers Squibb stand out. Both companies have a history of dividend payments and offer attractive yields. Pfizer, although facing challenges like the patent cliff, boasts a robust pipeline and a high dividend yield of around 6.1%, making it an appealing choice. On the other hand, Bristol Myers Squibb, with strengths in oncology and a lower payout ratio, also presents an enticing investment option. While Pfizer may have a slight edge due to its higher yield and pipeline, Bristol Myers Squibb's undervalued stock could offer long-term benefits.
Source: YAHOO